Orion (OEC)

NYSE Piața închisă

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

7.18 USD
2.89 USD
−0.10 (-1.37%)
După program

Ultima actualizare

Capitalizare bursieră
404.87M
Raport P/E
Raport P/FCF
11.53
Raport P/S
0.23
Valoare de întreprindere
1.37B
Sector economic
Industrie
Adresă
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

23 apr. 2026, 12:00 P.M.
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

24 feb. 2026, 15:00 P.M.
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

28 oct. 2025, 12:00 P.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

28 oct. 2025, 12:00 P.M.
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

18 iul. 2025, 12:00 P.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

09 iul. 2025, 13:00 P.M.
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

17 iun. 2025, 09:00 A.M.
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

17 iun. 2025, 09:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

21 mai 2025, 07:30 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

23 apr. 2025, 12:00 P.M.
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

21 mar. 2025, 13:00 P.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

07 ian. 2025, 09:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

07 ian. 2025, 09:00 A.M.
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

18 dec. 2024, 17:00 P.M.
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

18 dec. 2024, 17:00 P.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

24 oct. 2024, 19:50 P.M.
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

24 oct. 2024, 19:50 P.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

14 oct. 2024, 11:00 A.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14 oct. 2024, 11:00 A.M.
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

16 sept. 2024, 11:30 A.M.
Capitalizare bursieră
404.87M
Valoare de întreprindere
1.37B
Raport P/E
Raport P/B
1.07
Raport P/S
0.23
VE / EBITDA
6.46
VE / venituri
0.76
Profit pe acțiune
-1.58
Randament dividend
1.16%
Raport P/FCF
11.53
Raport P/CF
1.99
Flux de numerar liber
35.1M
Rentabilitatea capitalurilor proprii
-23.48%
Rentabilitatea activelor
-4.61%
Datorie / capitaluri proprii
2.67
Rata curentă
1
Rata rapidă
0.62
Numerar
0.08
Volum mediu
460.53K
Preț de referință fundamental
7.18

Cont de profit și pierdere

Element 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Venituri 459.5M 411.7M 450.9M 466.4M 477.7M
Profit brut 79.2M 77.7M 85.6M 98.4M 98.1M
Rezultat operațional 11.4M 13.5M -52.3M 32.1M 31.2M
EBITDA (rezultat înainte de dobândă, taxe, depreciere) 44.1M 41.3M 62.2M 64.1M 62.7M
Profit net -9.9M -21.1M -67.1M 9M 9.1M
EPS de bază -0.18 -0.37 -1.2 0.16 0.16
EPS diluat -0.18 -0.37 -1.2 0.16 0.16

Bilanț

Element 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total active 1.93B 1.91B 1.96B 2.02B 1.97B
Total pasive 1.55B 1.52B 1.56B 1.56B 1.5B
Capitaluri proprii 379.5M 384.6M 401.8M 466.5M 466.1M
Numerar și echivalente 50.5M 60.7M 51.3M 42.6M 37.5M
Active curente 661.5M 643.8M 683.5M 682.5M 688.6M
Pasive curente 659.7M 626.4M 635.3M 620.8M 601.9M

Flux de numerar

Element 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Flux de numerar operațional -12.4M 92.9M 68.8M 53.7M 400K
Flux de numerar din investiții -36.1M -48.7M -40.9M -42.2M -29.2M
Flux de numerar din finanțare 39.6M -35.7M -19.5M -7.8M 21.8M
Variația numerarului -8.9M 8.5M 8.4M 3.7M -7M
Tip Depunere Dată Legătură
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index 10-Q — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
form 4 Form 4 — Niewiem Sandra Vezi depunerea
form 4 Form 4 — Painter Corning F. Vezi depunerea
form 4 Form 4 — Puckett Jonathan A. Vezi depunerea
form 4 Form 4 — Quinones Carlos Vezi depunerea
form 4 Form 4 — Riveros Pedro Vezi depunerea
edgar index ARS — Orion S.A. Vezi depunerea
edgar index DEF 14A — Orion S.A. Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index PRE 14A — Orion S.A. Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index SCHEDULE 13G — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
form 4 Form 4 — Niewiem Sandra Vezi depunerea
form 4 Form 4 — Niewiem Sandra Vezi depunerea
form 4 Form 4 — Niewiem Sandra Vezi depunerea
form 4 Form 4 — Painter Corning F. Vezi depunerea
form 4 Form 4 — Painter Corning F. Vezi depunerea
form 4 Form 4 — Painter Corning F. Vezi depunerea
form 4 Form 4 — Quinones Carlos Vezi depunerea
form 4 Form 4 — Quinones Carlos Vezi depunerea
form 4 Form 4 — Quinones Carlos Vezi depunerea
form 4 Form 4 — Riveros Pedro Vezi depunerea
form 4 Form 4 — Riveros Pedro Vezi depunerea
form 4 Form 4 — Riveros Pedro Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index 10-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
ten k section 10-K — business Vezi depunerea
ten k section 10-K — mda Vezi depunerea
ten k section 10-K — risk_factors Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
form 4 Form 4 — Puckett Jonathan A. Vezi depunerea
edgar index 3 — Orion S.A. Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index 10-Q — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
eight k text 8-K — 8-K Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index 10-Q — Orion S.A. Vezi depunerea
edgar index SCHEDULE 13G/A — Orion S.A. Vezi depunerea
edgar index 8-K — Orion S.A. Vezi depunerea
edgar index SCHEDULE 13G/A — Orion S.A. Vezi depunerea
edgar index 3 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
edgar index 4 — Orion S.A. Vezi depunerea
form 4 Form 4 — GALVIN KERRY A Vezi depunerea